(PharmaNewsWire.Com, August 14, 2021 ) The global pharmaceutical contract development and manufacturing market is projected to reach USD 146.1 billion by 2025 from USD 100.7 billion in 2020, at a CAGR of 7.7% between 2020 and 2025. Market growth is driven mainly by factors such as rising demand for generics, increasing investments in pharmaceutical R&D, and investments in advanced manufacturing technologies by CDMOs. The increasing demand for biological therapies, growing focus on specialty medicines, growth in the nuclear medicines sector, and advancements in cell and gene therapies are also expected to offer market growth opportunities in the coming years.
The pharmaceutical manufacturing services segment accounted for the largest share of the service segment in the pharmaceutical contract development and manufacturing market in 2019.
On the basis of service, the pharmaceutical contract development and manufacturing market is broadly segmented into pharmaceutical manufacturing, biologics manufacturing, and drug development services. In 2019, the pharmaceutical manufacturing services segment accounted for the largest share of the pharmaceutical contract development and manufacturing market. The large share of this segment can be attributed to the limited finances of pharma manufacturers, capacity constraints, need for reductions in the time-to-market, complex manufacturing requirements, large investments required for establishing manufacturing facilities, and the growing pipeline, all of which have prompted the shift toward pharmaceutical contract manufacturing.
The big pharmaceutical companies segment accounted for the largest share of the end user segment in the pharmaceutical contract development and manufacturing market in 2019.
Based on end users, the pharmaceutical contract development and manufacturing market is segmented into big pharmaceutical companies, small & medium-sized pharmaceutical companies, generic pharmaceutical companies, and other end users. In 2019, big pharmaceutical companies accounted for the largest share of the pharmaceutical contract development and manufacturing market, and this trend is expected to continue during the forecast period. The large share of this end-user segment can be attributed to factors such as the high demand for end-to-end services in big pharmaceutical companies, rising pricing pressure and pipeline challenges in their operations (resulting in a shift toward contract development and manufacturing), and the growing need to streamline execution costs as a result of the patent expiry of blockbuster drugs.
The Asia Pacific region is the fastest-growing region of the pharmaceutical contract development and manufacturing market in 2019.
The Asia Pacific region is estimated to grow at the highest CAGR in the pharmaceutical contract development and manufacturing market during the forecast period, this is mainly due to factors such as increasing investments and expansions by big pharma companies in countries such as China, India, and South Korea.
Some of the prominent players in the pharmaceutical contract development and manufacturing market include Thermo Fisher Scientific Inc. (US), Catalent, Inc. (US), Lonza Group Ltd. (Switzerland), Recipharm AB (Sweden), AbbVie Inc. (US), Aenova Group (Germany), Almac Group (UK), Siegfried Holding AG (Switzerland), and Ingelheim International GmbH (Germany).
Lonza (Switzerland): The company offers integrated solutions to the pharmaceutical, biotech, consumer health, and specialty chemicals markets. As a contract development and manufacturing organization (CDMO), the company provides integrated solutions with various technologies that span the whole pharma value chain—from molecule to patient. The major end users of Lonza’s services include pharmaceutical companies, biotechnology companies, government research institutes, consumer & healthcare product manufacturers, formulators, and service companies. Lonza focused on geographical expansions in 2020, with major focus on its HPAPI, Capsugel, and bioconjugation-based services. During the ongoing COVID-19 pandemic, Lonza has been at the forefront and entered into agreements and partnerships with various other US-based firms to expedite the manufacturing process for COVID vaccines and drugs. These initiatives by the company are expected to help Lonza retain its leadership position in the market.
Thermo Fisher Scientific (US): Thermo Fisher is another prominent player operating in the pharmaceutical contract development and manufacturing market. The company has a strong geographic footprint serving over 400,000 customers in pharmaceutical and biotech companies. Thermo Fisher also has an extensive distribution channel across the globe. The firm registered more than USD 3.5 billion in revenues in 2019 from its contract development and manufacturing business, owing to its strategic acquisitions and unique value propositions.. The company’s extensive R&D activities enable it to increase its depth of capabilities in technologies, software, and services. The company also invested USD 150 million in its Pharma Services business segment to expand its manufacturing capacity for sterile liquid and lyophilized product development & commercial manufacturing.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
